News & Trends - Pharmaceuticals
Clinicians welcome expanded indication for BMS’ melanoma treatment

Pharma News: Bristol Myers Squibb Australia (BMS) is today welcoming the expanded Pharmaceutical Benefits Scheme (PBS) reimbursement of Opdivo (nivolumab) plus Yervoy (ipilimumab) to include patients with unresectable Stage III or IV malignant melanoma who have experienced disease recurrence whilst on, or within, six months of completion of adjuvant PD-1 inhibitor treatment.
According to Professor Georgina Long AO, dermatologist and Co-Medical Director of Melanoma Institute Australia (MIA), the listing helps to address a significant unmet clinical need for high-risk patients.
“Prior to today’s listing, melanoma patients who recurred while on, or within 6 months of, adjuvant anti-PD-1 therapy had limited treatment options, and were unable to access PBS-funded standard of care when they recurred, representing a high unmet clinical need,” said Prof Long.
“Today’s PBS announcement is a significant milestone for the melanoma community, and as clinicians, we welcome the availability of an additional treatment option for this patient group.”
Last year, the MIA collaborated with BMS, MSD and Novartis to launch the landmark melanoma report. It estimated that without critical action being taken, by 2030 a further 14,000 Australians will die from melanoma, 205,000 will be diagnosed with the disease, and the economic cost to the nation will be $8.7 billion. The report also highlighted that melanoma deaths in Australia exceed the road toll (1,384 vs 1,113), yet road safety funding dramatically exceeds melanoma awareness and prevention funding.
According to Leah Goodman, General Manager, Bristol Myers Squibb Australia, the support provided by the broader melanoma community was paramount in this PBS submission.
“BMS Australia acknowledges the collective efforts of the Medical Oncology community, patients, carers, and patient organisations who contributed to, and advocated for this listing.
“This PBS reimbursement provides broad, and equitable access to immunotherapy options for metastatic melanoma patients. We are proud of our efforts to address this unmet medical need, shaping the market to drive change for these most at risk patients,” Ms Goodman said.
At the American Society of Clinical Oncology (ASCO) Meeting 2022, Professor Long delivered an oral plenary session on the RELATIVITY-047 clinical trial, which showed the effectiveness of BMS’ Opdualag, a fixed-dose combination of LAG-3 inhibitor relatlimab and PD-1 immune checkpoint inhibitor Opdivo (nivolumab), for previously untreated advanced melanoma patients. The combination therapy continued to demonstrate a progression free survival (PFS) benefit vs monotherapy in patients with previously untreated metastatic or unresectable melanoma, consistent with the primary analysis. The combination treatment demonstrated a 20% reduction in risk of death and numerically improved overall survival (OS) rates, although statistical significance was not reached for this secondary endpoint.
Despite approvals in other countries, in July 2022, the PBAC did not recommend the listing of Opdualag for the treatment of patients with unresectable Stage III or IV malignant melanoma noting that “there is a low clinical need for Opdualag as there are existing effective treatment options available on the PBS” including BMS’ Opdivo and MSD’s Keytruda as monotherapy and BMS’ Yervoy + Opdivo in combination therapy.”
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - MedTech & Diagnostics

Government’s claim of progress in genomics falls flat while it fails to uphold the fundamental rights of Aussies
The government has unveiled Cancer Australia’s National Framework for Genomics in Cancer Control, a strategic plan designed to guide healthcare […]
MoreNews & Trends - Pharmaceuticals

Healthcare sector’s political donations: What to expect ahead of the federal election
Ahead of the upcoming federal election, attention turns to the financial contributions to major political parties. The Australian Electoral Commission’s […]
MoreNews & Trends - Pharmaceuticals

‘Underinvestment in gynae cancer has left critical gaps,’ says ANZGOG Chair
Ovarian cancer is the deadliest women’s cancer, with the latest statistics revealing a five-year survival rate of just 49%. Alarmingly, […]
MoreNews & Trends - MedTech & Diagnostics

Labor’s one-off funding a band aid for public hospitals while private sector left in limbo
The Federal Government has committed a one-off funding boost of $1.7 billion to public hospitals under a one-year extension to […]
More